Drugs / BL-ARC002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07591155 | May 2026 → Dec 2027 expected | cancer | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-23 | Sichuan Biokin Pharmaceutical Co., Ltd. | Regulatory 四川百利天恒药业股份有限公司自愿披露关于BL-ARC002用于晚期实体瘤治疗获得临床试验批准通知书的公告 cninfo.com.cn ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-23 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司自愿披露关于BL-ARC002用于晚期实体瘤治疗获得临床试验批准通知书的公告 cninfo.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-ARC002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07591155 ↗ |
| Route | Intravenous | “Administration by intravenous infusion for a cycle of 6 weeks.” NCT07591155 ↗ |